[go: up one dir, main page]

NO974403D0 - Reversible protease inhibitors - Google Patents

Reversible protease inhibitors

Info

Publication number
NO974403D0
NO974403D0 NO974403A NO974403A NO974403D0 NO 974403 D0 NO974403 D0 NO 974403D0 NO 974403 A NO974403 A NO 974403A NO 974403 A NO974403 A NO 974403A NO 974403 D0 NO974403 D0 NO 974403D0
Authority
NO
Norway
Prior art keywords
protease inhibitors
reversible protease
reversible
inhibitors
protease
Prior art date
Application number
NO974403A
Other languages
Norwegian (no)
Other versions
NO974403L (en
NO311573B1 (en
Inventor
James T Palmer
David Rasnick
Jeffrey L Klaus
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of NO974403D0 publication Critical patent/NO974403D0/en
Publication of NO974403L publication Critical patent/NO974403L/en
Publication of NO311573B1 publication Critical patent/NO311573B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19974403A 1995-03-24 1997-09-23 Reversible protease inhibitors NO311573B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40999695A 1995-03-24 1995-03-24
PCT/US1996/003844 WO1996030353A1 (en) 1995-03-24 1996-03-21 Reversible protease inhibitors

Publications (3)

Publication Number Publication Date
NO974403D0 true NO974403D0 (en) 1997-09-23
NO974403L NO974403L (en) 1997-11-17
NO311573B1 NO311573B1 (en) 2001-12-10

Family

ID=23622800

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19974403A NO311573B1 (en) 1995-03-24 1997-09-23 Reversible protease inhibitors

Country Status (15)

Country Link
EP (1) EP0817778A1 (en)
JP (1) JPH11503417A (en)
KR (1) KR19980703261A (en)
CN (1) CN1071751C (en)
AU (1) AU713492B2 (en)
CA (1) CA2216151A1 (en)
CZ (1) CZ298197A3 (en)
IL (1) IL117638A0 (en)
MY (1) MY113489A (en)
NO (1) NO311573B1 (en)
NZ (1) NZ305626A (en)
PL (1) PL322409A1 (en)
TW (1) TW470750B (en)
WO (1) WO1996030353A1 (en)
ZA (1) ZA962336B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2251714A1 (en) 1996-04-22 1997-10-30 Massachusetts Institute Of Technology Suppression of immune response via inhibition of cathepsin s
FI990171A7 (en) * 1996-07-30 1999-03-23 Arris Pharm Corp New compounds and compositions for treating diseases associated with tryptase activity
DE19817461A1 (en) * 1998-04-20 1999-10-21 Basf Ag New benzamide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
NZ509318A (en) * 1998-08-04 2002-10-25 Astrazeneca Ab Amide derivatives, their preparation and use in the treatment of diseases mediated by cytokines
BR9913947A (en) * 1998-09-25 2001-06-12 Astrazeneca Ab Amide derivative, process for preparing the same or a pharmaceutically acceptable salt or cleavable ester in vivo thereof, use thereof, and pharmaceutical composition
CA2360740A1 (en) * 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
PL364045A1 (en) * 1999-09-13 2004-12-13 Boehringer Ingelheim Pharmaceuticals, Inc. Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
DE60035218D1 (en) 1999-11-18 2007-07-26 Dendreon Corp NUCLEIC ACIDS THAT CODE ENDOTHELIAS, ENDOTHELIASES, AND THEIR USE
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
HU230538B1 (en) 2000-08-14 2016-11-28 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles and pharmaceutical compositions containing them
JP5140225B2 (en) 2000-08-14 2013-02-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Substituted pyrazoles
PT1309592E (en) 2000-08-14 2006-07-31 Ortho Mcneil Pharm Inc SUBSTITUTED PYRAZOLES
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
CN1642973A (en) 2000-09-06 2005-07-20 奥索-麦克尼尔药品公司 A method for treating allergies
WO2002048097A1 (en) * 2000-12-12 2002-06-20 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
CA2433520A1 (en) 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
WO2002077263A2 (en) 2001-03-22 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
US7105333B2 (en) 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
CA2447050A1 (en) 2001-05-14 2002-11-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
NZ531352A (en) * 2001-09-14 2006-01-27 Aventis Pharma Inc Novel compounds and compositions as cathepsin inhibitors
US6900237B2 (en) 2001-09-14 2005-05-31 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
BR0214104A (en) 2001-11-14 2004-09-28 Aventis Pharma Inc Oligopeptides and compositions containing them as cathepsin inhibitors
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof
ES2640814T3 (en) 2008-05-21 2017-11-06 Genesis Technologies Limited Selective caspase inhibitors and their uses
WO2010133000A1 (en) 2009-05-21 2010-11-25 New World Laboratories Inc. Selective caspase inhibitors and uses thereof
US8895497B2 (en) 2009-12-04 2014-11-25 Dcb-Usa, Llc Cathepsin S inhibitors
DK2697246T3 (en) 2011-04-15 2018-05-28 Genesis Tech Limited SELECTIVE CYSTEIN PROTEASE INHIBITORS AND USES THEREOF
KR101309578B1 (en) * 2011-05-06 2013-09-17 연세대학교 산학협력단 Dityrosine compounds having selectivity for cysteine proteases and method for monitoring cysteine proteases using the same
KR101385855B1 (en) * 2012-10-16 2014-04-22 이동익 Diaromatic amino acid-based substrate for detecting cathepsins
CN111601813A (en) * 2018-01-19 2020-08-28 株式会社大阪曹达 Organic silicon compound and rubber composition using same
EP3553521A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Gingivitis diagnostic methods, uses and kits

Also Published As

Publication number Publication date
AU713492B2 (en) 1999-12-02
NO974403L (en) 1997-11-17
PL322409A1 (en) 1998-01-19
NO311573B1 (en) 2001-12-10
IL117638A0 (en) 1996-07-23
CA2216151A1 (en) 1996-10-03
AU5367496A (en) 1996-10-16
ZA962336B (en) 1996-07-31
KR19980703261A (en) 1998-10-15
JPH11503417A (en) 1999-03-26
CZ298197A3 (en) 1998-03-18
CN1071751C (en) 2001-09-26
EP0817778A1 (en) 1998-01-14
MY113489A (en) 2002-03-30
NZ305626A (en) 2000-01-28
WO1996030353A1 (en) 1996-10-03
TW470750B (en) 2002-01-01
CN1184472A (en) 1998-06-10

Similar Documents

Publication Publication Date Title
NO974403D0 (en) Reversible protease inhibitors
NO20006716D0 (en) protease inhibitors
NO975742D0 (en) Reversible cysteine protease inhibitors
NO995433D0 (en) Protease inhibitors
PT936912E (en) CISTEIN PROTEASE INHIBITORS
FI965019A7 (en) Enzyme inhibitors
NO962269D0 (en) Enzyme inhibitors
NO932620D0 (en) AMINDIOL protease inhibitors
FI963597A7 (en) Isoprenyltransferase inhibitors
NO972930D0 (en) Fibronectin-adhesion inhibitors
NO973657D0 (en) Thrombin inhibitors
FI962904A7 (en) Metalloproteinase inhibitors
FI962905L (en) Metalloproteinase inhibitors
FI972160A0 (en) Matriisimetalloproteaasi inhibitors
DK0858464T3 (en) Thrombin inhibitors
NO995435D0 (en) Protease inhibitors
NO995434L (en) protease inhibitors
NO995268D0 (en) protease inhibitors
FI972198L (en) Metalloproteinase inhibitors
DE69431454D1 (en) Amylase inhibitors
BR9610514A (en) Cycloantihelmintic inhibitors
BR9612344A (en) Protease inhibitors
MA26429A1 (en) PROTEASE INHIBITORS
KR970703937A (en) Metalproteinase inhibitors
CY2007006I2 (en) ALIPOPROTEIN-B INHIBITORS

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN SEPTEMBER 2002